Roche presented new data on its Alzheimer’s disease portfolio at the CTAD 2026 conference, highlighting advances in both pharmaceuticals and diagnostics. Key updates include Phase Ib/IIa data for trontinemab showing rapid amyloid clearance, the start of Phase III PrevenTRON trial for preclinical Alzheimer’s, and a new Phase II trial for the oral NLRP3 inhibitor RG6434 targeting neuroinflammation. Roche also showcased real-world data supporting its Elecsys blood tests for earlier, accessible diagnosis. These developments reflect Roche’s multi-faceted approach to tackling Alzheimer’s by combining innovative therapies with improved diagnostic tools, aiming to slow or prevent disease progression.
Roche's new data on Alzheimer's disease treatments and diagnostics is presented here with Pluang's health sector market context. As of Nov 10, 2026 12:51 WIB, 122 of 150 priced health-sector US stocks rose while 25 fell. Notable movers include RLAY at USD 20.37 with a 9.52% increase and a typical hold time of 31 days on Pluang.
Wix.com reported Q3 2026 revenue of $570 million, a 13% year-over-year increase, fueled by strong performance from its Base44 platform, which is nearing $250 million in annual recurring revenue. The company launched Studio Two, an advanced AI-powered...
Valneva SE reported that 94% of participants maintained a strong immune response five years after a single dose of its chikungunya vaccine IXCHIQ®. The vaccine showed durable antibody persistence across all age groups, including those over 65, suppor...
U.S. spot Ethereum ETFs experienced net outflows totaling $184.51 million on November 9, marking the third consecutive day of withdrawals. The outflows were mainly driven by BlackRock's ETHA fund, which lost $119.28 million, surpassing inflows to the...
U.S. spot Bitcoin ETFs experienced net outflows for the third day in a row, with $201.08 million withdrawn on November 9, 2026. BlackRock’s IBIT fund led the outflows, losing $213.23 million, while Morgan Stanley’s MSBT was the only ETF to attract ne...
Autoliv, a global leader in automotive safety systems, has appointed Joachim Rosenberg as an independent director to its Board of Directors, increasing the board size from nine to ten members. Rosenberg brings extensive experience from his 20-year ca...
